Chemo plus immunotherapy for early HR+/HER2- breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests adding an immunotherapy drug (serplulimab) to standard chemotherapy for early-stage HR+/HER2- breast cancer. The goal is to see if the combination works better than chemo alone before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have early-stage breast cancer that is HR-positive and HER2-negative
- Your tumor is at least cT2 or has spread to lymph nodes
- You have not had any prior chemotherapy, hormone therapy, or immunotherapy for this cancer
- You do not have cancer that has spread to other parts of your body
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the immunotherapy drug serplulimab to standard chemotherapy for people with early-stage HR-positive, HER2-negative breast cancer. It aims to see if this combination can improve outcomes before surgery.
This trial tests a combination of chemotherapy, an immunotherapy drug, and two different schedules of radiation before surgery for a common type of breast cancer. The goal is to find which radiation approach works better and to improve outcomes.
This trial tests whether adding two newer drugs to standard chemotherapy can improve outcomes for women with early-stage breast cancer that is hormone-receptor positive and has low HER2. The goal is to see if a combination of immunotherapy and targeted therapy helps shrink tumors before surgery.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can help treat HR+/HER2- breast cancer. It is for women with early-stage breast cancer that has not spread to other parts of the body.
This trial tests a combination of chemotherapy, immunotherapy, and targeted radiation given before surgery for a certain type of breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
Hear when a new Breast Cancer Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.